With the ink barely dry on outgoing commissioner Marty Makary’s resignation, another top regulator may be heading for the exit at the FDA. | With the ink barely dry on outgoing commissioner Marty ...
With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...
Doceree has bold ambitions to bring a new software category to pharma brand teams, one that reshapes campaign deployment in ...
Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in ...
Despite a prolonged period of policy uncertainty in the U.S.—and the ripple effects across the global life sciences and ...
When President Donald Trump rolled out his plan to levy a 100% tariff rate on patented pharmaceutical products and ...
After doubling sales of its Biogen-partnered Alzheimer’s disease med Leqembi in its 2025 fiscal year, Eisai figures the crawl to its blockbuster ambitions will hit a stride in 2026, when it expects | ...
As biologics have come to supersede small molecules in the biopharma industry’s pipeline, the mounting complexity behind the ...
A new survey undertaken by the Harris Poll for Johnson & Johnson has shown how standard forms of surgery and treatment for ...
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
As President Donald Trump lands in Beijing, one major industry is missing from his business delegation—pharma. | As President ...
With a new CEO prepared to take the reins next month and three key launches on deck for 2026 and 2027, Takeda is ready to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results